FR 167344

structure given in first source

Also Known As:

3-bromo-8-(2,6-dichloro-3-(N-((E)-4-(N,N-dimethylcarbamoyl)cinnamidoacetyl)-N-methylamino)benzyloxy)-2-methylimidazo(1,2-a)pyridine hydrochloride; FR 172357; FR-167344; FR167344

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - FR 167344: 1

Related Diseases

1.	Inflammation (Inflammations) 12/01/1997 - "FR167344 may have therapeutic potential against inflammatory diseases by oral administration and it may be a useful tool for studying the involvement of B2 receptors in various in vivo models of inflammation." 12/01/1997 - "1. The effects of a novel, potent and orally active nonpeptide bradykinin B2 receptor antagonist, FR167344 (N-[N-[3-[(3-bromo-2-methylimidazo[1,2-a]pyridin-8-yl)oxymethyl]-2 ,4-dichlorophenyl]-N-methylaminocarbonylmethyl]-4-(dimethylamin ocarbonyl) cinnamylamide hydrochloride) were tested in three different in vivo models of inflammation. " 12/01/1997 - "Effects of a nonpeptide bradykinin B2 receptor antagonist, FR167344, on different in vivo animal models of inflammation."
2.	Pancreatitis 12/01/1997 - "5. These results show that FR167344 is an orally active, anti-inflammatory and anti-nociceptive agent in carrageenin-induced paw oedema, kaolin-induced writhing and caerulein-induced pancreatitis. "

Related Drugs and Biologics

1.	Bradykinin B2 Receptor
2.	Kaolin
3.	Carrageenan
4.	Ceruletide

Related Therapies and Procedures

1.	Oral Administration